by Robert Langreth and Gerry Smith, Bloomberg News Credit: Unsplash/CC0 Public DomainAn experimental version of Eisai Co’s Alzheimer’s drug that might be given in patients’ homes exceeded the power of Leqembi, its approved infused formulation, in an early study that could pave the way to bolstering uptake. After six months of treatment, an injected form...
